Lonza that supplies an active ingredient of Increlex (mecasermin [rDNA origin] Injection) is at present working with FDA to address these issues.
The interruption in the supply is expected in the second quarter of 2013 in the US and in the third quarter 2013 in Europe and the rest of the world.
Increlex is an aqueous solution for injection containing human insulin-like growth factor-1 (rhIGF-1) produced by recombinant DNA technology.